Acceleron Pharma Reports Second Quarter 2014 Financial Results

Acceleron Pharma Reports Second Quarter 2014 Financial Results

August 12, 2014

--Encouraging interim data presented from five phase 2 clinical trials --

-- Two additional phase 2 studies initiated --

-- Pipeline advancement and expansion demonstrate potential value of late-stage clinical opportunities --

BIND Therapeutics Reports Second Quarter 2014 Financial Results

BIND Therapeutics Reports Second Quarter 2014 Financial Results

August 7, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today reported financial results for the second quarter ended June 30, 2014.

Is this the next big leap for organ transplants?

Is this the next big leap for organ transplants?

August 7, 2014

For decades an ordinary picnic cooler has been the the best way to transport donated organs. One entrepreneur thinks we can do much better — and save more lives.

WHEN THE REVELATION CAME, it came in the middle of the night. Waleed Hassanein was a first-year surgical resident at Georgetown University School of Medicine, on the path to becoming a cardiac surgeon. He had worked toward that career for years — in Egypt, in London, and now at a prestigious American hospital. His family, having produced its share of doctors, would proudly add him to the list.

T2 Biosystems Announces Pricing of Initial Public Offering

T2 Biosystems Announces Pricing of Initial Public Offering

August 7, 2014

LEXINGTON, Mass., Aug. 7, 2014 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. today announced the pricing of its initial public offering of 5,200,000 shares of common stock at a public offering price of $11.00 per share, before underwriting discounts. All of the common stock is being offered by T2 Biosystems. In addition, T2 Biosystems has granted the underwriters a 30-day option to purchase up to an additional 780,000 shares of common stock from the company at the public offering price.

Jazz Pharmaceuticals and Concert Pharmaceuticals Provide a Phase 1 Clinical Trial Update on JZP-386

Jazz Pharmaceuticals and Concert Pharmaceuticals Provide a Phase 1 Clinical Trial Update on JZP-386

July 21, 2014

DUBLIN & LEXINGTON, Mass.--()--J

Seres Health Completes Enrollment in a Clinical Study for SER-109 in Recurrent Clostridium difficile Infection and Announces Positive Preliminary Data

Seres Health Completes Enrollment in a Clinical Study for SER-109 in Recurrent Clostridium difficile Infection and Announces Positive Preliminary Data

July 16, 2014

SER-109 demonstrated remarkably high clinical cure rate and excellent safety profile

Concert Pharmaceuticals Announces FDA Lifts Partial Clinical Hold for CTP-354, A Novel Drug Candidate for Spasticity

Concert Pharmaceuticals Announces FDA Lifts Partial Clinical Hold for CTP-354, A Novel Drug Candidate for Spasticity

July 16, 2014

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDA

Acceleron Pharma Appoints Terrence C. Kearney to its Board of Directors

Acceleron Pharma Appoints Terrence C. Kearney to its Board of Directors

July 14, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 14, 2014-- Acceleron Pharma Inc. (NASDAQ:XLRN), a biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced the appointment of Terrence C. Kearney to its Board of Directors and to the position of Chair of the Audit Committee.

Flagship Ventures Adds Pharma Industry Veteran Roger J. Pomerantz, M.D., F.A.C.P. as Senior Partner

Flagship Ventures Adds Pharma Industry Veteran Roger J. Pomerantz, M.D., F.A.C.P. as Senior Partner

July 14, 2014

CAMBRIDGE, Mass., /PRNewswire/ -- Flagship Ventures, a leading venture capital and venture creation firm focused on healthcare and sustainability, today announced the appointment of Roger J. Pomerantz, M.D., F.A.C.P., as a Senior Partner. In this role, Dr. Pomerantz will provide strategic counsel and support to the Flagship team as well as to portfolio companies through board and advisory roles. Dr. Pomerantz recently joined as President and Chief Executive Officer of Seres Health, a Flagship VentureLabs™-founded company.

Concert Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for CTP-499

Concert Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for CTP-499

July 8, 2014

--Provides Direction for Phase 3 Development in Diabetic Nephropathy--